Kidney disease drugmaker Maze files for IPO | BioPharma Dive
3 days ago · Maze is the second biotech to seek a Nasdaq IPO in recent weeks. China-based drugmaker Ascentage Pharma on Dec. 27 filed a plan to list its American depositary shares. Launched in 2019, Maze has raised almost $500 million in private funding, including from investors Third Rock Ventures and Arch Venture Partners.
Maze Opens 2025 IPO Class to Advance Kidney Disease Programs
3 days ago · Maze’s IPO comes on the heels of its oversubscribed Series D funding round, which infused the biotech with $115 million in funding to support the development of its kidney disease pipeline. ... BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations ...
Third Rock-Backed Maze Therapeutics Reveals Profit in US ... - U.S. News
4 days ago · (Reuters) - Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its paperwork for a U.S. initial public offering (IPO) filing on ...
Maze charts path through clinical development with planned IPO
3 days ago · Maze applied to be listed on the Nasdaq under the ticker symbol "MAZE," according to the filing. Related Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open'
Maze Therapeutics IPO: Third Rock-backed Maze Therapeutics …
2 days ago · Maze said it earned $9.03 million for the nine months ended Sept. 30, 2024, compared with a loss of $73.84 million in the year-ago period. Advt The terms of the IPO were not disclosed in the offering.
News & Press - Maze Therapeutics
Nov 13, 2024 · Maze Therapeutics Reports Positive First-in-Human Data from Phase 1 Healthy Volunteer Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (AKD)
Maze Therapeutics Announces Oversubscribed $115 Million …
Dec 3, 2024 · MZE829, an oral, APOL1 inhibitor, is being evaluated as a treatment for APOL1 kidney disease (AKD), including in patients with focal segmental glomerulosclerosis (FSGS), with a Phase 2 trial...
FTC Seeks to Block Sanofi’s Acquisition of Rare Disease Drug that ...
Dec 11, 2023 · Sanofi is a monopoly supplier of Food and Drug Administration (FDA) approved drugs to treat the disease. According to the FTC’s complaint, Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001—threatens to undermine this monopoly as the first oral medication available for Pompe disease patients.
Statement Regarding the Termination of Sanofi’s Proposed …
On December 11, 2023, the FTC sued to block Sanofi’s acquisition of an exclusive license to Maze’s Phase 2-ready developmental drug—a glycogen synthase 1 inhibitor called MZE001— alleging the deal would eliminate a nascent competitor poised to challenge Sanofi’s monopoly in the Pompe disease therapy market. After the FTC issued an ...
Sanofi strikes a $150M deal for Maze’s Pompe disease drug
May 1, 2023 · In a deal announced Monday, Sanofi will acquire rights to develop and commercialize Maze’s drug candidate MZE001, which is slated to begin a Phase 2 study later this year. Maze has raised $381 million in private financing since launching in 2019.
- Some results have been removed